Baseline prostate-specific antigen levels in midlife predict lethal prostate cancer

Journal of Clinical Oncology

Volumn 34, Issue 23, 2016, Pages 2705-2711

  Preston, Mark A ^a   Batista, Julie L ^a,b,c   Wilson, Kathryn M ^b   Carlsson, Sigrid V ^e,f   Gerke, Travis ^b   Sjoberg, Daniel D ^e   Dahl, Douglas M ^d   Sesso, Howard D ^a,b   Feldman, Adam S ^a,d   Gann, Peter H ^g   Kibel, Adam S ^b   Vickers, Andrew J ^e   Mucci, Lorelei A ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Department of Biostatistics   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f UNIVERSITY OF GOTHENBURG   (Sweden)

^g UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CANCER PATIENT; CANCER RISK; CANCER SCREENING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FOLLOW UP; HUMAN; LIFE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIDLIFE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; BLOOD; CASE CONTROL STUDY; EPIDEMIOLOGY; MORTALITY; ODDS RATIO; PREDICTIVE VALUE; PROSTATE TUMOR; UNITED STATES;

ADULT; AREA UNDER CURVE; CASE-CONTROL STUDIES; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; ROC CURVE; UNITED STATES;

EID: 84981271627     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.66.7527     Document Type: Article

References (28)

1. Hugosson J, Carlsson S, Aus G, et al: Mortality results from the Göteborg randomised populationbased prostate-cancer screening trial. Lancet Oncol 11:725-732, 2010
2. Schröder FH, Hugosson J, Roobol MJ, et al: Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 366:981-990, 2012
3. Schröder FH, Hugosson J, Roobol MJ, et al: Screening and prostate cancer mortality: Results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 384:2027-2035, 2014
4. Welch HG, Gorski DH, Albertsen PC: Trends in metastatic breast and prostate cancer: Lessons in cancer dynamics. N Engl J Med 373:1685-1687, 2015
5. Vickers AJ, Sjoberg DD, Ulmert D, et al: Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen. BMC Med 12:26, 2014
6. Loeb S, Bjurlin MA, Nicholson J, et al: Overdiagnosis and overtreatment of prostate cancer. Eur Urol 65:1046-1055, 2014
7. Moul JW: Screening for prostate cancer in military populations. Mil Med 170:905-914, 2005
8. Preston DM, Levin LI, Jacobson DJ, et al: Prostate-specific antigen levels in young white and black men 20 to 45 years old. Urology 56:812-816, 2000
9. Tang P, Sun L, Uhlman MA, et al: Baseline PSA as a predictor of prostate cancer-specific mortality over the past 2 decades: Duke University experience. Cancer 116:4711-4717, 2010
10. Vickers AJ, Ulmert D, Sjoberg DD, et al: Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: Case-control study. BMJ 346:f2023, 2013
11. Lilja H, Cronin AM, Dahlin A, et al: Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer 117:1210-1219, 2011
12. Loeb S, Carter HB, Catalona WJ, et al: Baseline prostate-specific antigen testing at a young age. Eur Urol 61:1-7, 2012
13. Kuller LH, Thomas A, Grandits G, et al: Elevated prostate-specific antigen levels up to 25 years prior to death from prostate cancer. Cancer Epidemiol Biomarkers Prev 13:373-377, 2004
14. Fang J, Metter EJ, Landis P, et al: Low levels of prostate-specific antigen predict long-Term risk of prostate cancer: Results from the Baltimore Longitudinal Study of Aging. Urology 58:411-416, 2001
15. Loeb S, Roehl KA, Antenor JA, et al: Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology 67:316-320, 2006
16. Stattin P, Vickers AJ, Sjoberg DD, et al: Improving the specificity of screening for lethal prostate cancer using prostate-specific antigen and a panel of kallikrein markers: A nested case-control study. Eur Urol 68:207-213, 2015
17. Zlotta AR, Egawa S, Pushkar D, et al: Prevalence of prostate cancer on autopsy: Cross-sectional study on unscreened Caucasian and Asian men. J Natl Cancer Inst 105:1050-1058, 2013
18. Jahn JL, Giovannucci E, Stampfer MJ: The high prevalence of undiagnosed prostate cancer at autopsy: Implications for epidemiology and treatment of prostate cancer in the prostate-specific antigen-era. Int J Cancer 137:2795-2802, 2015
19. Vertosick EA, Poon BY, Vickers AJ: Relative value of race, family history and prostate specific antigen as indications for early initiation of prostate cancer screening. J Urol 192:724-728, 2014
20. Hennekens CH, Eberlein K: A randomized trial of aspirin and beta-carotene among U.S. physicians. Prev Med 14:165-168, 1985
21. Gann PH, Ma J, Catalona WJ, et al: Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: A prospective evaluation. J Urol 167:2427-2434, 2002
22. Ulmert D, Becker C, Nilsson JA, et al: Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-Term storage at-20 degrees C. Clin Chem 52:235-239, 2006
23. Rubin DB: Multiple Imputation for Nonresponse in Surveys. New York, NY, Wiley, 1987
24. Stattin P, Carlsson S, Holmström B, et al: Prostate cancer mortality in areas with high and low prostate cancer incidence. J Natl Cancer Inst 106: dju007, 2014
25. Carlsson S, Assel M, Sjoberg D, et al: Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: Population based cohort study. BMJ 348: g2296, 2014
26. Legler JM, Feuer EJ, Potosky AL, et al: The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States. Cancer Causes Control 9: 519-527, 1998
27. Chornokur G, Dalton K, Borysova ME, et al: Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer. Prostate 71:985-997, 2011
28. Whittemore AS, Lele C, Friedman GD, et al: Prostate-specific antigen as predictor of prostate cancer in black men and white men. J Natl Cancer Inst 87:354-360, 1995